References

Prevalence of diabetic retinopathy in the United States, 2005–2008

10.1001/jama.2010.1111 · 2010 · External reference

National diabetes fact sheet: general information and national estimates on diabetes in the United States. Atlanta, GA: U.S. Department of Health and Human Services

2009 · External reference

Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8

1981 · External reference

Visual loss following panretinal photocoagulation for proliferative diabetic retinopathy

10.1016/s0161-6420(85)34016-2 · 1985 · External reference

Early photocoagulation for diabetic retinopathy. ETDRS report number 9

1991 · External reference

Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings

10.1001/archophthalmol.2008.565 · 2009 · External reference

Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1

10.1001/archopht.1985.01050120030015 · 1985 · External reference

A novel treatment for proliferative diabetic retinopathy: anti-vascular endothelial growth factor therapy

10.1001/jamaophthalmol.2015.5079 · 2016 · External reference

Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial

10.1001/jama.2015.15217 · 2015 · External reference

Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial

10.1001/jamaophthalmol.2018.3255 · 2018 · External reference

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

10.1056/nejmoa1414264 · 2015 · External reference

The 2016 American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) database

10.1016/j.ophtha.2017.12.001 · 2018 · External reference

Anti–vascular endothelial growth factor and panretinal photocoagulation use after protocol S for proliferative diabetic retinopathy

10.1016/j.oret.2020.07.018 · 2021 · External reference

Fifteen-year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute’s patients participating in the Diabetic Retinopathy Study

10.1016/s0161-6420(91)32326-1 · 1991 · External reference

Loss to follow-up among patients with proliferative diabetic retinopathy in clinical practice

10.1016/j.ajo.2020.03.011 · 2020 · External reference

Patients presenting emergently with proliferative diabetic retinopathy: follow-up and factors associated with compliance

10.1097/iae.0000000000002481 · 2020 · External reference

Loss to follow-up in patients with proliferative diabetic retinopathy after panretinal photocoagulation or intravitreal anti-VEGF injections

10.1016/j.ophtha.2018.02.034 · 2018 · External reference

Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation versus intravitreal anti–vascular endothelial growth factor

10.1016/j.ophtha.2018.07.027 · 2019 · External reference

Anti–vascular endothelial growth factor therapy for diabetic retinopathy: consequences of inadvertent treatment interruptions

10.1016/j.ajo.2019.03.005 · 2019 · External reference

Cost evaluation of panretinal photocoagulation versus intravitreal ranibizumab for proliferative diabetic retinopathy

10.1016/j.ophtha.2016.05.037 · 2016 · External reference